Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered IPG1094 in Healthy Adult Participants

NCT05112159 is registered in ClinicalTrials.gov with Nanjing Immunophage Biotech Co., Ltd as lead sponsor.

NCT NCT05112159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05112159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered IPG1094 in Healthy Adult Participants
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2021
Completion date
July 25, 2022
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers